Britain | EUROPESAYS.COM
  • /
  • Europe
  • France
  • Spain
  • Canada
  • Australia
  • Africa
  • Football
  • Tennis
  • Golf
  • PM
  • England
    • London
    • Cambridgeshire
    • Cumbria
    • Derbyshire
    • Devon
    • Dorset
    • East Sussex
    • Essex
    • Gloucestershire
    • Hampshire
    • Hertfordshire
  • Britain
  • …
    • Germany
    • Italy
    • Ukraine
    • Poland
    • Netherlands
    • Russia
    • Iran
    • Japan
    • AI
  • @
  • AstraZeneca
  • BAE Systems
  • Barclays
  • BP
  • Britain
  • British American Tobacco
  • Compass Group
  • Diageo
  • Glencore
  • GSK
  • HSBC
  • Lloyds Banking Group
  • London
  • London Stock Exchange Group
  • National Grid
  • NatWest
  • Reckitt Benckiser
  • Rio Tinto
  • Rolls-Royce
  • Shell
  • Standard Chartered
  • UK
  • Unilever
Britain | EUROPESAYS.COM
  • /
  • Europe
  • France
  • Spain
  • Canada
  • Australia
  • Africa
  • Football
  • Tennis
  • Golf
  • PM
  • England
    • London
    • Cambridgeshire
    • Cumbria
    • Derbyshire
    • Devon
    • Dorset
    • East Sussex
    • Essex
    • Gloucestershire
    • Hampshire
    • Hertfordshire
  • Britain
  • …
    • Germany
    • Italy
    • Ukraine
    • Poland
    • Netherlands
    • Russia
    • Iran
    • Japan
    • AI
  • @

Browsing Tag

EGFR

4 posts
GGSK
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy
Read More

China’s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy

  • September 4, 2026
China’s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy September 4, 2026 | Friday…
GGSK
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion — BigGo Finance
Read More

Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion — BigGo Finance

  • September 4, 2026
Hutchmed (00013.HK; HCM.US) announced on September 3 that its subsidiary, Hutchison Whampoa Pharmaceutical (Shanghai), has entered into an…
AAstraZeneca
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
Read More

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

  • September 1, 2026
WILMINGTON, Del., September 01, 2026–(BUSINESS WIRE)–AstraZeneca today announced the successful completion of the previously announced exclusive license agreement…
AAstraZeneca
Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
Read More

Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy

  • July 14, 2026
Dizal grants AstraZeneca worldwide rights to develop and commercialise Zegfrovy Dizal will receive an upfront payment of $600M,…
Britain | EUROPESAYS.COM
www.europesays.com